1. Sander, J. D. & Joung, J. K. CRISPR–Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347–355 (2014).

2. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

3. Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).

4. Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR–Cas9. Nat. Biotechnol. 33, 102–106 (2015).

5. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).

6. Liao, H. K. et al. Use of the CRISPR–Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat. Commun. 6, 6413 (2015).

7. Dever, D. P. et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 539, 384–389 (2016).

8. Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403–407 (2016).

9. Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411 (2016).

10. Lin, Y. N. et al. CRISPR–Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473–7485 (2014).

11. Cradick, T. J., Fine, E. J., Antico, C. J. & Bao, G. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584–9592 (2013).

12. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR–Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013).

13. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013).

14. Lee, C. M., Cradick, T. J., Fine, E. J. & Bao, G. Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing. Mol. Ther. 24, 475–487 (2016).

15. Dow, L. E. et al. Inducible in vivo genome editing with CRISPR–Cas9. Nat. Biotechnol. 33, 390–394 (2015).

16. Nihongaki, Y., Kawano, F., Nakajima, T. & Sato, M. Photoactivatable CRISPR–Cas9 for optogenetic genome editing. Nat. Biotechnol. 33, 755–760 (2015).

17. Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 (2008).

18. Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328–333 (2016).

19. Wang, Y. et al. Systemic dissemination of viral vectors during intratumoral injection. Mol. Cancer Ther. 2, 1233–1242 (2003).

20. Stanley, S. A., Sauer, J., Kane, R. S., Dordick, J. S. & Friedman, J. M. Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles. Nat. Med. 21, 92–98 (2015).

21. Mannix, R. J. et al. Nanomagnetic actuation of receptor-mediated signal transduction. Nat. Nanotech. 3, 36–40 (2008).

22. Wheeler, M. A. et al. Genetically targeted magnetic control of the nervous system. Nat. Neurosci. 19, 756–761 (2016).

23. Qiu, Y. et al. Magnetic forces enable controlled drug delivery by disrupting endothelial cell–cell junctions. Nat. Commun. 8, 15594 (2017).

24. Sammet, S. Magnetic resonance safety. Abdom. Radiol. 41, 444–451 (2016).

25. Airenne, K. J. et al. Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol. Ther. 21, 739–749 (2013).

26. Mansouri, M. et al. Highly efficient baculovirus-mediated multigene delivery in primary cells. Nat. Commun. 7, 11529 (2016).

27. Chen, C. Y., Lin, C. Y., Chen, G. Y. & Hu, Y. C. Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications. Biotechnol. Adv. 29, 618–631 (2011).

28. Kost, T. A., Condreay, J. P. & Jarvis, D. L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 23, 567–575 (2005).

29. Hindriksen, S. et al. Baculoviral delivery of CRISPR–Cas9 facilitates efficient genome editing in human cells. PLoS ONE 12, e0179514 (2017).

30. Hofmann, C. & Strauss, M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 5, 531–536 (1998).

31. Strauss, R. et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol. Ther. 15, 193–202 (2007).

32. Swift, S. L. et al. Evaluating baculovirus as a vector for human prostate cancer gene therapy. PLoS ONE 8, e65557 (2013).

33. Wu, C. et al. Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy. Mol. Ther. 17, 2058–2066 (2009).

34. Haeseleer, F., Imanishi, Y., Saperstein, D. A. & Palczewski, K. Gene transfer mediated by recombinant baculovirus into mouse eye. Invest. Ophthalmol. Vis. Sci. 42, 3294–3300 (2001).

35. Kaikkonen, M. U., Maatta, A. I., Yla-Herttuala, S. & Airenne, K. J. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. Mol. Ther. 18, 987–992 (2010).

36. Raty, J. K. et al. Enhanced gene delivery by avidin-displaying baculovirus. Mol. Ther. 9, 282–291 (2004).

37. Sun, S. et al. Monodisperse MFe 2 O 4 (M = Fe, Co, Mn) nanoparticles. J. Am. Chem. Soc. 126, 273–279 (2004).

38. Tong, S., Hou, S., Ren, B., Zheng, Z. & Bao, G. Self-assembly of phospholipid-PEG coating on nanoparticles through dual solvent exchange. Nano Lett. 11, 3720–3726 (2011).

39. Torchilin, V. P. TAT peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60, 548–558 (2008).

40. Small, D. A. & Moore, N. F. Measurement of surface charge of baculovirus polyhedra. Appl. Environ. Microbiol. 53, 598–602 (1987).

41. Boyce, F. M. & Bucher, N. L. R. Baculovirus-mediated gene transfer into mammalian cells. Proc. Natl Acad. Sci. USA 93, 2348–2352 (1996).

42. Ohkawa, T., Volkman, L. E. & Welch, M. D. Actin-based motility drives baculovirus transit to the nucleus and cell surface. J. Cell Biol. 190, 187–195 (2010).

43. Matilainen, H. et al. Baculovirus entry into human hepatoma cells. J. Virol. 79, 15452–15459 (2005).

44. Kataoka, C. et al. Baculovirus GP64-mediated entry into mammalian cells. J. Virol. 86, 2610–2620 (2012).

45. Romet-Lemonne, G. & Jegou, A. Mechanotransduction down to individual actin filaments. Eur. J. Cell Biol. 92, 333–338 (2013).

46. Shen, H., Tong, S., Bao, G. & Wang, B. Structural responses of cells to intracellular magnetic force induced by superparamagnetic iron oxide nanoparticles. Phys. Chem. Chem. Phys. 16, 1914–1920 (2014).

47. Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995).